CLDX
Celldex Therapeutics, Inc.
There isn't enough reported data to score CLDX yet.
HIMS
Hims & Hers Health, Inc.
There isn't enough reported data to score HIMS yet.
CLDX Fundamentals
| Metric | Status |
|---|---|
| Weak | |
| Weak | |
| Weak | |
| Unavailable |
CLDX's revenue, profitability and cash flow are currently weak. There isn't enough data to rate its balance sheet.
HIMS Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Weak | |
| Stable | |
| Strong |
HIMS's revenue and balance sheet are currently strong, and its cash flow is stable, but its profitability is weak.
CLDX PE Valuation
CLDX has no meaningful PE right now: it lost money over the past year.
HIMS PE Valuation
HIMS has no meaningful PE right now: it lost money over the past year.
CLDX Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses steady | |
| Strong decline | |
| -- | |
| Limited | |
| Low |
Analysts expect CLDX's revenue to decline, with its earnings and profitability holding steady. However, they disagree widely on these estimates.
HIMS Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Turning to a loss | |
| Strong growth | |
| Stable | |
| Limited | |
| Low |
Analysts expect HIMS's revenue to grow, but its earnings to decline. However, they disagree widely on these estimates.
CLDX Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2023 | -$2.65 | -$0.39 |
| Q2 2023 | -$2.41 | -$0.27 |
| Q1 2023 | -$2.53 | -$0.82 |
| Q4 2022 | -$2.40 | -$0.76 |
| Q3 2022 | -$2.26 | -$0.50 |
| Q2 2022 | -$2.14 | -$0.47 |
| Q1 2022 | -$1.71 | +$0.12 |
| Q4 2021 | -$1.64 | +$0.50 |
HIMS has the stronger earnings trend. Trailing diluted EPS is down 263% for CLDX versus HIMS down 257%.
HIMS Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.83 | -257% |
| Q2 2026 | -$0.63 | -180% |
| Q1 2026 | -$0.09 | -113% |
| Q4 2025 | $0.51 | -3.8% |
| Q3 2025 | $0.53 | +20% |
| Q2 2025 | $0.79 | +888% |
| Q1 2025 | $0.68 | +$0.69 |
| Q4 2024 | $0.53 | +$0.64 |
HIMS has swung to a loss: it lost $0.83 per share over the past year, after a profit the year before.
CLDX Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q2 2026 | $22K | -97% |
| Q1 2026 | $15K | -98% |
| Q4 2025 | $121K | -90% |
| Q2 2025 | $730K | -71% |
| Q1 2025 | $695K | +346% |
| Q4 2024 | $1.2M | -72% |
| Q3 2024 | $3.2M | +110% |
| Q2 2024 | $2.5M | +832% |
CLDX's revenue has slid since its 2023 peak: $0 last quarter.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2026 | -366468% | -357721 points |
| Q1 2026 | -562900% | -553873 points |
| Q4 2025 | -72027% | -67259 points |
| Q2 2025 | -8748% | -6893 points |
| Q1 2025 | -9027% | +17004 points |
| Q4 2024 | -4768% | -3615 points |
| Q3 2024 | -1634% | +1085 points |
| Q2 2024 | -1854% | +10536 points |
CLDX's operating margin was −366468% last quarter, down 357441 points from the same quarter a year ago, near the bottom of its range since 2019.
HIMS Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $890.4M | +49% |
| Q2 2026 | $753.2M | +38% |
| Q1 2026 | $608.1M | +3.8% |
| Q4 2025 | $617.8M | +28% |
| Q3 2025 | $599M | +49% |
| Q2 2025 | $544.8M | +73% |
| Q1 2025 | $586M | +111% |
| Q4 2024 | $481.1M | +95% |
HIMS has the edge over CLDX on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -7.4% | -9.4 points |
| Q2 2026 | -13% | -18 points |
| Q1 2026 | -13% | -23 points |
| Q4 2025 | 1.5% | -2.4 points |
| Q3 2025 | 2% | -3.6 points |
| Q2 2025 | 4.9% | +1.4 points |
| Q1 2025 | 9.9% | +6.3 points |
| Q4 2024 | 3.9% | +4 points |
HIMS has the edge over CLDX on profitability, with a higher operating margin.
CLDX Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$66.7M | -$17.6M |
| Q2 2026 | -$60.6M | -$15.9M |
| Q1 2026 | -$67.2M | -$12.6M |
| Q4 2025 | -$65.2M | -$32M |
| Q3 2025 | -$49.1M | +$6.8M |
| Q2 2025 | -$44.7M | -$15.1M |
| Q1 2025 | -$54.6M | -$13.7M |
| Q4 2024 | -$33.2M | -$33K |
CLDX has burned cash in almost every quarter: −$260M over the past year, against −$182M the year before.
HIMS Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $26M | -67% |
| Q2 2026 | -$68.2M | +$1.3M |
| Q1 2026 | $53.1M | +5.9% |
| Q3 2025 | $79.3M | -7% |
| Q2 2025 | -$69.5M | -230% |
| Q1 2025 | $50.1M | +94% |
| Q3 2024 | $85.3M | +238% |
| Q2 2024 | $53.6M | +219% |
HIMS has the edge over CLDX on cash generation, producing positive trailing cash flow while its opponent burns cash.
CLDX Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.9% | +691K shares |
| 1 year | +67% | +31.6M shares |
| 3 years | +351% | +61.1M shares |
CLDX has 79M diluted shares, up 67% from a year ago.
HIMS Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.9% | +2.1M shares |
| 1 year | -6% | -14.9M shares |
| 3 years | +11% | +23.7M shares |
| 5 years | +17% | +33.8M shares |
HIMS has the edge over CLDX on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q4 2025 | $80.5M |
| Q3 2025 | $9.5M |
| Q2 2025 | — |
| Q1 2025 | — |
| Q4 2024 | $5M |
| Q3 2024 | $30M |
| Q2 2024 | $19.9M |
| Q1 2024 | $28.1M |
CLDX Net Leverage
CLDX's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
HIMS Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q1 2026 | -5.9x | Net Cash |
| Q4 2025 | -1.4x | Net Cash |
| Q3 2025 | -2.2x | Net Cash |
| Q2 2025 | -7.3x | Net Cash |
| Q1 2025 | -2.1x | Net Cash |
| Q4 2024 | -2.8x | Net Cash |
| Q3 2024 | -2.9x | Net Cash |
| Q2 2024 | -5.5x | Net Cash |
HIMS has more cash than debt.
CLDX Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 40.7 | Neutral |
| Stochastic | 11.5 | Oversold |
CLDX's weekly RSI is 41 (neutral) and its Stochastic is 12 (oversold).
HIMS Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 36.0 | Neutral |
| Stochastic | 23.0 | Neutral |
HIMS's weekly RSI is 36 (neutral) and its Stochastic is 23 (neutral).
CLDX PE vs Healthcare Sector
CLDX has no meaningful PE right now: it lost money over the past year.
HIMS PE vs Healthcare Sector
| Metric | HIMS | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
HIMS has no meaningful PE right now: it lost money over the past year.
CLDX Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $29.7 | 4.1% below |
| 20 week MA | $35.1 | 19% below |
| 50 week MA | $31.6 | 9.7% below |
| 100 week MA | $27.1 | 5.2% above |
| 200 week MA | $31.2 | 8.4% below |
CLDX has the edge over HIMS on trend strength, trading above more of its moving averages.
HIMS Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $27.3 | 28% below |
| 20 week MA | $29.2 | 32% below |
| 50 week MA | $27.7 | 29% below |
| 100 week MA | $35.9 | 45% below |
| 200 week MA | $24.4 | 19% below |
HIMS is in a downtrend: it's below all five of its weekly moving averages, and 19% below its 200-week average.
CLDX Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $2.22 | $17.5 | +687% |
| 2021 | $17.5 | $42.0 | +140% |
| 2022 | $42.0 | $44.1 | +5% |
| 2023 | $44.1 | $39.7 | -10% |
| 2024 | $39.7 | $25.4 | -36% |
| 2025 | $25.4 | $26.4 | +4% |
| 2026 YTD | $26.4 | $28.5 | +8.1% |
CLDX has the edge over HIMS on returns for 2026, with the stronger performance.
HIMS Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $9.89 | $15.0 | +51% |
| 2021 | $15.0 | $6.65 | -56% |
| 2022 | $6.65 | $6.43 | -3.3% |
| 2023 | $6.43 | $8.90 | +38% |
| 2024 | $8.90 | $26.6 | +198% |
| 2025 | $26.6 | $34.3 | +29% |
| 2026 YTD | $34.3 | $19.7 | -42% |
HIMS's yearly returns have swung widely, from +198% in 2024 to −56% in 2021. It's down 42% so far in 2026.